Phio Pharma Shares Are Trading Higher On Cancer Immunotherapies Pact With AgonOx


Phio Pharmaceuticals Corp (NASDAQ: PHIO) has entered into a clinical development collaboration with AgonOx Inc to develop novel T cell-based cancer immunotherapies.

  • The collaboration will use Phio's lead INTASYL based product candidate PH-762 and AgonOx's "double positive" tumor-infiltrating lymphocyte (TIL) technology.
  • The study is expected to start enrolling patients later this year.
  • Preclinical data presented at SITC 2020 by AgonOx in collaboration with Phio show that treating the DP CD8 TIL with Phio's PH-762 increases the tumor-killing activity of the CD8 DP TIL even further (a two-fold increase). 
  • Under the terms of the agreement, AgonOx will receive financial support for the trial from Phio, and Phio will receive certain future development milestones and sales-related royalty payments from AgonOx's DP TIL technology.
  • Price Action: PHIO shares were trading 11.5% higher at $3.19 in premarket trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareContractsFDAGeneralCancer Immunotherapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!